CA3147731A1 - Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms - Google Patents

Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms Download PDF

Info

Publication number
CA3147731A1
CA3147731A1 CA3147731A CA3147731A CA3147731A1 CA 3147731 A1 CA3147731 A1 CA 3147731A1 CA 3147731 A CA3147731 A CA 3147731A CA 3147731 A CA3147731 A CA 3147731A CA 3147731 A1 CA3147731 A1 CA 3147731A1
Authority
CA
Canada
Prior art keywords
buffer
acid
composition
bladder
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3147731A
Other languages
English (en)
French (fr)
Inventor
C. Lowell Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3147731A1 publication Critical patent/CA3147731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3147731A 2019-07-18 2020-07-14 Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms Abandoned CA3147731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875745P 2019-07-18 2019-07-18
US62/875,745 2019-07-18
PCT/US2020/041977 WO2021011566A1 (en) 2019-07-18 2020-07-14 Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms

Publications (1)

Publication Number Publication Date
CA3147731A1 true CA3147731A1 (en) 2021-01-21

Family

ID=74211195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147731A Abandoned CA3147731A1 (en) 2019-07-18 2020-07-14 Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms

Country Status (6)

Country Link
US (1) US20220273587A1 (enExample)
EP (1) EP3998932A4 (enExample)
JP (1) JP2022550658A (enExample)
AU (1) AU2020315353A1 (enExample)
CA (1) CA3147731A1 (enExample)
WO (1) WO2021011566A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702790B2 (en) 2019-06-13 2026-08-11 Hollister Incorporated Reusable urinary catheter kits
LT3952973T (lt) 2019-06-13 2023-07-10 Hollister Incorporated Daugkartinio naudojimo šlapimo kateterio produktai
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183461B1 (en) * 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US20050238733A1 (en) * 2000-01-05 2005-10-27 Richard Henry Topical anesthesia of the urinary bladder
CA2554489A1 (en) * 2004-01-28 2005-08-11 The Regents Of The University Of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
EA201391014A1 (ru) * 2011-01-06 2014-01-30 С. Лоуэлл Парсонс Способ производства композиции, содержащей местный анестетик, гепариноид и буфер
US20150359816A1 (en) * 2013-01-28 2015-12-17 Urigen Pharmaceuticals, Inc. Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer
JP7862118B2 (ja) 2017-04-12 2026-05-19 ウリゲン ファーマシューティカルズ、インコーポレイテッド 改善された安定性を備えた注射器中に局所麻酔薬、緩衝液、およびグルコサミノグリカンを含む製品

Also Published As

Publication number Publication date
EP3998932A1 (en) 2022-05-25
US20220273587A1 (en) 2022-09-01
EP3998932A4 (en) 2023-08-16
AU2020315353A1 (en) 2022-03-10
WO2021011566A1 (en) 2021-01-21
JP2022550658A (ja) 2022-12-05

Similar Documents

Publication Publication Date Title
US20120196830A1 (en) Kits and improved compositions for treating lower urinary tract disorders
CA2899636C (en) Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer
JP2017061503A (ja) 局所麻酔剤、ヘパリノイド、及び緩衝剤を含む組成物を製造する方法
AU2020315353A1 (en) Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
CA3061891A1 (en) Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
WO2007073397A1 (en) Kits and improved compositions for treating lower urinary tract discorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220531

FZDE Discontinued

Effective date: 20240116